Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ekso Bionics Holdings (EKSO) over the last 13 years, with Q3 2025 value amounting to -$437000.0.

  • Ekso Bionics Holdings' Cash from Financing Activities fell 10931.57% to -$437000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 5974.38%. This contributed to the annual value of $7.8 million for FY2024, which is 213247.13% up from last year.
  • Per Ekso Bionics Holdings' latest filing, its Cash from Financing Activities stood at -$437000.0 for Q3 2025, which was down 10931.57% from $616000.0 recorded in Q2 2025.
  • In the past 5 years, Ekso Bionics Holdings' Cash from Financing Activities ranged from a high of $38.7 million in Q1 2021 and a low of -$437000.0 during Q3 2025
  • Over the past 4 years, Ekso Bionics Holdings' median Cash from Financing Activities value was $616000.0 (recorded in 2025), while the average stood at $5.6 million.
  • As far as peak fluctuations go, Ekso Bionics Holdings' Cash from Financing Activities skyrocketed by 667249.58% in 2021, and later tumbled by 19022.99% in 2024.
  • Quarter analysis of 4 years shows Ekso Bionics Holdings' Cash from Financing Activities stood at $38.7 million in 2021, then plummeted by 99.1% to $348000.0 in 2023, then crashed by 190.23% to -$314000.0 in 2024, then crashed by 39.17% to -$437000.0 in 2025.
  • Its last three reported values are -$437000.0 in Q3 2025, $616000.0 for Q2 2025, and $3.5 million during Q1 2025.